An Emerging Human Parechovirus Type 5 Causing Sepsis-Like Illness in Infants in Australia.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
03 10 2019
Historique:
received: 20 09 2019
revised: 01 10 2019
accepted: 01 10 2019
entrez: 19 10 2019
pubmed: 19 10 2019
medline: 22 9 2020
Statut: epublish

Résumé

Human parechovirus (HPeV), particularly type 3 (HPeV3), is an important cause of sepsis-/meningitis-like illness in young infants. Laboratory records identified a total of ten HPeV-positive cases in Southeastern Australia between January and July 2019. The HPeV present in these cases were typed by Sanger sequencing of the partial viral capsid protein 1 (VP1) region and selected cases were further characterised by additional Sanger or Ion Torrent near-full length virus sequencing. In seven of the ten cases, an HPeV type 5 (HPeV5) was identified, and in the remaining three cases, an HPeV type 1 was identified. The HPeV5-positive cases were infants under the age of 3 months admitted to hospital with fever, rash, lethargy and/or sepsis-like clinical signs. Near full-length virus sequencing revealed that the HPeV5 was most likely a recombinant virus, with structural genes most similar to an HPeV5 from Belarus in 2018, and a polymerase gene most similar to an HPeV3 from Australia in 2013/14. While HPeV5 is not typically associated with severe clinical signs, the HPeV5 identified here may have been able to cause more severe disease in young infants through the acquisition of genes from a more virulent HPeV.

Identifiants

pubmed: 31623340
pii: v11100913
doi: 10.3390/v11100913
pmc: PMC6832754
pii:
doi:

Substances chimiques

Capsid Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Gen Virol. 2010 May;91(Pt 5):1229-38
pubmed: 20089803
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
J Gen Virol. 2007 Mar;88(Pt 3):831-41
pubmed: 17325355
J Clin Virol. 2017 Mar;88:1-7
pubmed: 28081453
Emerg Infect Dis. 2015 Jul;21(7):1144-52
pubmed: 26082289
Thorax. 2018 Oct;73(10):969-979
pubmed: 29247051
Front Cell Infect Microbiol. 2018 Aug 22;8:294
pubmed: 30211126
Clin Infect Dis. 2015 Jan 15;60(2):228-36
pubmed: 25301212
J Gen Virol. 2010 Jan;91(Pt 1):145-54
pubmed: 19759239
Sci Rep. 2017 Mar 14;7:44423
pubmed: 28290509
PLoS One. 2016 Apr 29;11(4):e0154769
pubmed: 27128974
J Clin Virol. 2013 Sep;58(1):328-30
pubmed: 23867007
J Virol. 1999 Jan;73(1):152-60
pubmed: 9847317
Clin Infect Dis. 2019 Aug 13;:null
pubmed: 31406985
J Gen Virol. 2004 Feb;85(Pt 2):391-8
pubmed: 14769896
J Virol. 1994 Dec;68(12):8232-8
pubmed: 7966616
J Virol. 2007 Jan;81(2):1013-21
pubmed: 17005640
PLoS Pathog. 2010 Aug 26;6(8):e1001066
pubmed: 20865167
Med J Aust. 2018 May 7;208(8):365-369
pubmed: 29716506
J Virol. 2012 Sep;86(18):9964-75
pubmed: 22761387
Sci Rep. 2018 Jun 6;8(1):8686
pubmed: 29875375
J Clin Virol. 2010 Jul;48(3):202-7
pubmed: 20472496
Am J Respir Cell Mol Biol. 2008 May;38(5):517-23
pubmed: 18063839
Sci Rep. 2017 Jun 20;7(1):3861
pubmed: 28634337
Sci Rep. 2019 Jun 20;9(1):8906
pubmed: 31222066
Sci Rep. 2019 Mar 14;9(1):4602
pubmed: 30872719
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
J Virol. 2001 Oct;75(20):10000-4
pubmed: 11559835
Emerg Infect Dis. 2019 Jul;25(7):1384-1388
pubmed: 31211683
J Clin Virol. 2017 Aug;93:37-39
pubmed: 28605724

Auteurs

Anthony Chamings (A)

Geelong Center for Emerging Infectious Diseases, Geelong, VI 3220, Australia. anthony.chamings@deakin.edu.au.
Deakin University, School of Medicine, Geelong, VI 3220, Australia. anthony.chamings@deakin.edu.au.

Kwee Chin Liew (KC)

Barwon Health, University Hospital Geelong, Geelong, VI 3220, Australia. KWEECHIN.LIEW@barwonhealth.org.au.
Australian Clinical Labs, Geelong Laboratory, Geelong, VI 3220, Australia. KWEECHIN.LIEW@barwonhealth.org.au.

Emily Reid (E)

Barwon Health, University Hospital Geelong, Geelong, VI 3220, Australia. EMILY.REID@barwonhealth.org.au.

Eugene Athan (E)

Geelong Center for Emerging Infectious Diseases, Geelong, VI 3220, Australia. EUGENE.ATHAN@barwonhealth.org.au.
Deakin University, School of Medicine, Geelong, VI 3220, Australia. EUGENE.ATHAN@barwonhealth.org.au.
Barwon Health, University Hospital Geelong, Geelong, VI 3220, Australia. EUGENE.ATHAN@barwonhealth.org.au.

Amy Raditsis (A)

Deakin University, School of Medicine, Geelong, VI 3220, Australia. araditsi@deakin.edu.au.
Barwon Health, University Hospital Geelong, Geelong, VI 3220, Australia. araditsi@deakin.edu.au.

Peter Vuillermin (P)

Deakin University, School of Medicine, Geelong, VI 3220, Australia. peter.vuillermin@deakin.edu.au.
Barwon Health, University Hospital Geelong, Geelong, VI 3220, Australia. peter.vuillermin@deakin.edu.au.

Yano Yoga (Y)

Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute, Melbourne, VI 3000, Australia. Yano.Yoga@mh.org.au.

Leon Caly (L)

Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute, Melbourne, VI 3000, Australia. Leon.Caly@vidrl.org.au.

Julian Druce (J)

Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute, Melbourne, VI 3000, Australia. Julian.Druce@mh.org.au.

Soren Alexandersen (S)

Geelong Center for Emerging Infectious Diseases, Geelong, VI 3220, Australia. soren.alexandersen@deakin.edu.au.
Deakin University, School of Medicine, Geelong, VI 3220, Australia. soren.alexandersen@deakin.edu.au.
Barwon Health, University Hospital Geelong, Geelong, VI 3220, Australia. soren.alexandersen@deakin.edu.au.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH